Drug class
Substituted benzamide antiemetic and prokinetic; dopamine D2-receptor antagonist
Mechanism of action
Antagonises dopamine D2 receptors in the chemoreceptor trigger zone and gastrointestinal tract, reducing emetic signalling and facilitating upper gastrointestinal motility. Experimental data also report 5-HT4-receptor agonist effects in isolated human atrial tissue; their clinical relevance to its GI use is not established.
General use cases
- Nausea and vomiting
- Functional dyspepsia and selected upper gastrointestinal motility disorders in countries where bromopride is authorised; approved indications and formulations vary by jurisdiction
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
